ATE300306T1 - Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung - Google Patents

Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung

Info

Publication number
ATE300306T1
ATE300306T1 AT02794984T AT02794984T ATE300306T1 AT E300306 T1 ATE300306 T1 AT E300306T1 AT 02794984 T AT02794984 T AT 02794984T AT 02794984 T AT02794984 T AT 02794984T AT E300306 T1 ATE300306 T1 AT E300306T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
rhinological
ophthalmological
concerns
pharmaceutical
Prior art date
Application number
AT02794984T
Other languages
German (de)
English (en)
Inventor
Dorothea Gross
Frank Holzer
Original Assignee
Ursapharm Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7708986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE300306(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ursapharm Arzneimittel Gmbh filed Critical Ursapharm Arzneimittel Gmbh
Application granted granted Critical
Publication of ATE300306T1 publication Critical patent/ATE300306T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02794984T 2001-12-12 2002-12-11 Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung ATE300306T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10161110A DE10161110A1 (de) 2001-12-12 2001-12-12 Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
PCT/DE2002/004527 WO2003049747A1 (de) 2001-12-12 2002-12-11 Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung

Publications (1)

Publication Number Publication Date
ATE300306T1 true ATE300306T1 (de) 2005-08-15

Family

ID=7708986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02794984T ATE300306T1 (de) 2001-12-12 2002-12-11 Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung

Country Status (11)

Country Link
US (1) US20050164979A1 (enExample)
EP (1) EP1455803B2 (enExample)
JP (1) JP3994089B2 (enExample)
CN (1) CN1310651C (enExample)
AT (1) ATE300306T1 (enExample)
AU (1) AU2002360895A1 (enExample)
CA (1) CA2468771C (enExample)
DE (2) DE10161110A1 (enExample)
ES (1) ES2244831T5 (enExample)
MX (1) MXPA04005387A (enExample)
WO (1) WO2003049747A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20318634U1 (de) 2003-11-13 2004-02-26 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden
DE102004002001A1 (de) * 2004-01-14 2005-08-11 Reinmüller, Johannes, Dr.med. Mittel zur Behandlung von entzündlichen Erkrankungen
CN1285382C (zh) * 2004-12-20 2006-11-22 凌沛学 含海藻糖和玻璃酸的鼻腔用药传递系统及其制备方法
DE102005055275A1 (de) * 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
MX2009000885A (es) 2006-07-25 2009-02-05 Osmotica Corp Soluciones oftalmicas.
WO2008068866A1 (en) * 2006-11-30 2008-06-12 Menicon Co., Ltd. Ophthalmic composition
KR100927579B1 (ko) * 2006-12-13 2009-11-23 주식회사 엘지생명과학 히아루론산 및/또는 그것의 염을 함유하는 아토피성피부염의 개선 및 치료를 위한 조성물
FR2919185B1 (fr) 2007-07-23 2010-09-10 Ard Sa Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de l'etat des muqueuses
DE202008016517U1 (de) * 2008-12-12 2009-03-05 Ratiopharm Gmbh Wässrige Zusammensetzung enthaltend Dexpanthenol und Natriumchlorid
US9473792B2 (en) * 2009-11-06 2016-10-18 Texas Instruments Incorporated Method and system to improve the performance of a video encoder
FR2962044B1 (fr) * 2010-04-21 2013-02-22 Horus Pharma Emulsion lacrymimetique
JP2013534527A (ja) * 2010-07-02 2013-09-05 ブライエン ホールデン ビジョン インスティテュート コンタクトレンズ乳頭結膜炎及びアレルギー性眼疾患の予防及び処置のための組成物
DE202010012255U1 (de) * 2010-09-07 2010-11-18 Krewel Meuselbach Gmbh Nasenspray
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
CN102579478A (zh) * 2012-03-30 2012-07-18 济南康众医药科技开发有限公司 玻璃酸钠在制备药物中的应用
DE102012011447B4 (de) 2012-05-14 2022-11-24 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Verwendung von Pantothenol oder Pantothensäure in einem Kombinationstherapeutikum für die Behandlung von Rhinitis zur Verringerung der systemischen Resorption imidazolinbasierter alpha-Sympathomimetika
EP2664330A1 (de) * 2012-05-15 2013-11-20 F. Holzer GmbH Zusammensetzung und Arzneimittel enthaltend Omega-3-Fettsäuren sowie einen Glucosaminoglucan
CN102989045B (zh) * 2012-11-12 2015-02-25 广州共禾医药科技有限公司 生物相容的水性组合物及其用途
CA2945604C (en) * 2014-08-08 2022-08-23 Shenzhen Hightide Biopharmaceutical, Ltd. Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof
EP2985019B1 (en) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
EP2985027B1 (en) 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Nasal composition comprising mixture of hyaluronic acids and saline solution
ES2827426T3 (es) 2015-03-26 2021-05-21 Dmg Italia Srl Composición oftálmica para la protección corneal
DE102016203696A1 (de) * 2016-03-07 2017-09-07 Ursapharm Arzneimittel Gmbh Ophthalmologische Zusammensetzung
DE102016204472A1 (de) * 2016-03-17 2017-09-21 Ursapharm Arzneimittel Gmbh Kit zur kosmetischen Behandlung des Auges und der Haut und Kosmetikum zur Anwendung am Auge und auf der Haut
TWI609957B (zh) * 2016-06-27 2018-01-01 晶碩光學股份有限公司 用以處理隱形眼鏡之溶液及隱形眼鏡的包裝系統
JP7044467B2 (ja) * 2017-01-16 2022-03-30 ロート製薬株式会社 眼科組成物
DE202017104738U1 (de) * 2017-07-31 2018-08-01 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Zusammensetzung für die nasale Applikation
CN107260657B (zh) * 2017-08-03 2019-02-05 广东莱恩医药研究院有限公司 一种缓释型连翘苷滴眼液及其制备方法
ES2972897T3 (es) * 2017-08-10 2024-06-17 Elixir Ilac Arastirma Ve Gelistirme A S Composiciones descongestionantes nasales que comprenden mentol, dexpantenol e hialuronato de sodio
WO2019202017A1 (en) * 2018-04-18 2019-10-24 i.com medical GmbH High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease
EP3781116A1 (en) * 2018-04-18 2021-02-24 i.com Medical GmbH High molecular weight hyaluronic acid for enhancing epithelial survival and reconstitution of body surfaces
US11576926B2 (en) * 2018-09-12 2023-02-14 Neilos S.r.l. Composition for use in the prevention and/or treatment of epistaxis
US12268706B2 (en) 2019-01-31 2025-04-08 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
EP3827818A1 (en) * 2019-11-26 2021-06-02 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic composition
CN112870216A (zh) * 2021-01-29 2021-06-01 张宽才 一种药物组合物及制剂和用途
EP4039248A1 (en) * 2021-02-04 2022-08-10 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic composition
FR3151481A1 (fr) * 2023-07-28 2025-01-31 Horus Pharma Emulsion de type huile dans eau comprenant de l’acide hyaluronique et du dexpanthenol

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
JPS6479103A (en) * 1987-06-09 1989-03-24 Lion Corp External preparation
DE3832401A1 (de) † 1988-09-23 1990-03-29 Cassella Ag Pharmazeutische zubereitung zur behandlung entzuendeter nasenschleimhaeute
US5141741A (en) * 1988-12-09 1992-08-25 Lion Corporation Anti-sunburn skin-care preparation
IL101056A (en) † 1992-02-24 1997-03-18 Res & Dev Co Ltd Composition for nasal treatment
IT1273011B (it) * 1994-07-25 1997-07-01 Trhecnopharma S A Preparato oftalmico per l'uso come lacrima artificiale
DE19517251A1 (de) * 1995-05-11 1996-11-14 Klosterfrau Mcm Vetrieb Gmbh Verwendung von Dexpanthenol zur Behandlung trockener Nasenschleimhäute
DE19541919C2 (de) † 1995-11-10 1997-11-20 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE19549421C2 (de) † 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
KR100514963B1 (ko) * 1997-07-11 2005-09-15 도레이 가부시끼가이샤 4,5-에폭시모르피난 유도체를 함유하는 안정한 의약품 조성물
DE19923829A1 (de) * 1999-05-17 2000-11-23 Ulrich Kluegel Hyaluronat-Wirkstoff-Wasser-Komplex, dessen Herstellung und Verwendung
PL198969B1 (pl) * 2001-01-09 2008-08-29 Louis Johan Wagenaar Zastosowanie dekspantenolu jako składnika kompozycji do pielęgnacji soczewek kontaktowych

Also Published As

Publication number Publication date
MXPA04005387A (es) 2005-03-23
CN1602198A (zh) 2005-03-30
ES2244831T3 (es) 2005-12-16
JP3994089B2 (ja) 2007-10-17
WO2003049747A8 (de) 2003-10-02
CA2468771C (en) 2007-01-30
CA2468771A1 (en) 2003-06-19
DE50203788D1 (de) 2005-09-01
EP1455803A1 (de) 2004-09-15
US20050164979A1 (en) 2005-07-28
DE10161110A1 (de) 2003-06-26
EP1455803B2 (de) 2016-03-23
JP2006501133A (ja) 2006-01-12
ES2244831T5 (es) 2016-05-10
EP1455803B1 (de) 2005-07-27
CN1310651C (zh) 2007-04-18
AU2002360895A1 (en) 2003-06-23
WO2003049747A1 (de) 2003-06-19

Similar Documents

Publication Publication Date Title
ATE300306T1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
CR8012A (es) Clavo endomedular destinado al tratamiento de fracturas de femur proximal
TW200626526A (en) Pharmaceutical compositions for the treatment of neoplasms
GB0108592D0 (en) Therapeutic agents
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
MY144318A (en) Methods of treating hiv infection.
BR0110028A (pt) Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
BR0213358A (pt) Uso de flibanserina
EP1545483A4 (en) NON-NUCLEOSIDIC INHIBITORS OF INVERSE TRANSCRIPTASES
GB0223040D0 (en) Therapeutic compounds
BRPI0418384A (pt) composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
WO2006034001A3 (en) Methods of treating hiv infection
AU2003273843A8 (en) Use of skin-protecting substances
CL2004001421A1 (es) Composicion farmaceutica que comprende un compuesto derivado de 1,4-dipiperidin-4-il-piperazina; y su uso para la prevencion y/o tratamiento del dolor.
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
MY134059A (en) Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
BR0104005A (pt) Composição farmacêutica para a prevenção ou para o tratamento de uma doença associada com um excesso de produção de il-2
NO20042586L (no) Behandlingsfremgangsmate
BR0212274A (pt) Uso de estrogênios não-feminilizantes como agentes retinoprotetores para o tratamento de glaucoma
PT1351680E (pt) Utilizacao de anetole-ditioletiona na prevencao e tratamento da tenotoxicidade induzida por um medicamento
HRP20050497B1 (hr) Uporaba levocetirizina za liječenje stalnog alergijskog rinitisa
TW200519078A (en) 2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture